Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright's price target points to a potential upside of 376.19% from the company's current price.
Other research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Stifel Nicolaus set a $5.00 price objective on Pyxis Oncology in a research report on Thursday, November 5th. Wedbush reduced their price objective on Pyxis Oncology from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Friday, November 6th. Royal Bank Of Canada lifted their target price on Pyxis Oncology from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, November 6th. Finally, William Blair upgraded Pyxis Oncology from a "market perform" rating to an "outperform" rating in a report on Friday. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Pyxis Oncology presently has an average rating of "Moderate Buy" and a consensus target price of $8.71.
Read Our Latest Stock Analysis on Pyxis Oncology
Pyxis Oncology Trading Up 19.1%
NASDAQ:PYXS opened at $1.68 on Friday. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55. The company has a 50-day moving average of $2.16 and a 200-day moving average of $2.15. The firm has a market cap of $200.94 million, a price-to-earnings ratio of -1.29 and a beta of 1.41.
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. On average, research analysts forecast that Pyxis Oncology will post -1.12 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in PYXS. T3 Companies LLC purchased a new stake in shares of Pyxis Oncology in the 3rd quarter valued at approximately $61,000. Commonwealth Equity Services LLC boosted its stake in Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company's stock worth $114,000 after purchasing an additional 6,295 shares during the period. Jump Financial LLC purchased a new position in Pyxis Oncology during the 3rd quarter worth approximately $150,000. Empowered Funds LLC purchased a new position in Pyxis Oncology during the 3rd quarter worth approximately $219,000. Finally, Goldman Sachs Group Inc. raised its stake in Pyxis Oncology by 221.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 147,598 shares of the company's stock valued at $344,000 after purchasing an additional 101,698 shares during the period. 39.07% of the stock is owned by hedge funds and other institutional investors.
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company's pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology's broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.